The estimated Net Worth of Michael Gilman is at least 940 千$ dollars as of 15 March 2021. Michael Gilman owns over 4,696 units of Scholar Rock Corp stock worth over 325,519$ and over the last 20 years he sold SRRK stock worth over 425,379$. In addition, he makes 188,661$ as Independent Director at Scholar Rock Corp.
Sign up
Michael Gilman SRRK stock SEC Form 4 insiders trading
Michael has made over 6 trades of the Scholar Rock Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 4,696 units of SRRK stock worth 308,011$ on 15 March 2021.
The largest trade he's ever made was exercising 30,000 units of Scholar Rock Corp stock on 13 September 2004 worth over 1,336,200$. On average, Michael trades about 4,001 units every 355 days since 2004. As of 15 March 2021 he still owns at least 37,459 units of Scholar Rock Corp stock.
You can see the complete history of Michael Gilman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Gilman biography
Dr. Michael Gilman, Ph.D. is Independent Director of the company since November 2013. Dr. Gilman is currently Chief Executive Officer for Arrakis Therapeutics, Inc., a role he has served in since 2016. From October 2016 to April 2019, Dr. Gilman was Chief Executive Officer for Obsidian Therapeutics, Inc. Previously, from 2014 to 2016, Dr. Gilman was Founder and Chief Executive Officer of Padlock Therapeutics, Inc. Prior to Padlock, Dr. Gilman served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec Inc. from 2012 to 2013. He joined Biogen Idec Inc. in 2012 following its acquisition of Stromedix, Inc., where he was Founder and Chief Executive Officer. Prior to founding Stromedix in 2006, from 1999 to 2005, Dr. Gilman served in a variety of capacities, most recently as Executive Vice President, Research at Biogen Idec. From 1994 to 1999, Dr. Gilman was at ARIAD Pharmaceuticals, Inc., where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Dr. Gilman was on the scientific staff of Cold Spring Harbor Laboratory in New York. He also serves on the Board of Directors of Obsidian Therapeutics, Inc. and Novartis Venture Fund, and on the Scientific Advisory Board of FutuRx, an Israeli biotech accelerator. He previously served on the Board of Directors of X4 Pharmaceuticals, Inc. from September 2014 to March 2019. Dr. Gilman was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a Ph.D. in Biochemistry from University of California, Berkeley, and a S.B. in Life Sciences from Massachusetts Institute of Technology. Our Board of Directors believes that Dr. Gilman's extensive experience in the pharmaceuticals industry qualifies him to serve on our Board of Directors.
What is the salary of Michael Gilman?
As the Independent Director of Scholar Rock Corp, the total compensation of Michael Gilman at Scholar Rock Corp is 188,661$. There are 6 executives at Scholar Rock Corp getting paid more, with Dr. Nagesh K. Mahanthappa MBA, Ph.D. having the highest compensation of 1,372,681$.
How old is Michael Gilman?
Michael Gilman is 65, he's been the Independent Director of Scholar Rock Corp since 2013. There are no older and 13 younger executives at Scholar Rock Corp.
Insiders trading at Scholar Rock Corp
Over the last 6 years, insiders at Scholar Rock Corp have traded over 8,613,447$ worth of Scholar Rock Corp stock and bought 8,895,194 units worth 64,726,758$ . The most active insiders traders include Timothy A Springer、Srinivas Akkaraju、Amir Nashat. On average, Scholar Rock Corp executives and independent directors trade stock every 55 days with the average trade being worth of 1,953,616$. The most recent stock trade was executed by Caryn Parlavecchio on 16 August 2024, trading 1,451 units of SRRK stock currently worth 13,538$.
What does Scholar Rock Corp do?
scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s
What does Scholar Rock Corp's logo look like?
Complete history of Michael Gilman stock trades at Biogen Inc、Scholar Rock Corp
Scholar Rock Corp executives and stock owners
Scholar Rock Corp executives and other stock owners filed with the SEC include:
-
Dr. Nagesh K. Mahanthappa MBA, Ph.D.,
Interim CEO & Director -
Yung Chyung,
Chief Medical Officer -
Alan Buckler,
Chief Scientific Officer -
Edward H. Myles M.B.A., MBA,
CFO & Head of Bus. Operations -
Dr. Gregory John Carven Ph.D.,
Chief Scientific Officer -
David Hallal,
Independent Chairman of the Board -
Michael Gilman,
Independent Director -
Kristina Burow,
Independent Director -
Edward Myles,
Chief Financial Officer -
Tony Kingsley,
President, Chief Executive Officer, Director -
Erin Moore,
Senior Vice President - Finance -
Catherine Hu,
IR Contact Officer -
Ryan Iarrobino,
Sr. VP of Clinical Devel. & Operations -
Erin Moore,
Sr. VP of Fin. -
Dr. George G. Nomikos M.D., Ph.D.,
Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area -
Lisa Amaya Price,
Sr. VP of HR -
Dr. Yung H. Chyung M.D.,
Chief Medical Officer -
Caryn Parlavecchio,
Chief HR Officer -
Junlin Ho J.D.,
Gen. Counsel & Corp. Sec. -
Public Equities, L.P.Artal ...,
-
Stuart A Kingsley,
President and CEO -
Richard Brudnick,
-
Bio Capital Gp, Llc Samsara...,
-
Srinivas Akkaraju,
-
Venture Management Co. Vi, ...,
-
Rhonda M. Chicko,
Chief Financial Officer -
Elan Ezickson,
COO & Head of Corp.Development -
Venture Fund Viii, L.P.Arch...,
-
International S.C.A.Invus P...,
-
Jeffrey S. Flier,
-
Katie Peng,
-
Jay T. Backstrom,
CHIEF EXECUTIVE OFFICER -
Timothy A Springer,
10% owner -
Mo Qatanani,
CHIEF SCIENTIFIC OFFICER -
Tracey Sacco,
CHIEF COMMERCIAL OFFICER -
Jing L. Marantz,
CHIEF MEDICAL OFFICER -
Joshua Reed,
-
Akshay Vaishnaw,
-
Gregory John Carven,
Chief Scientific Officer -
Amir Nashat,
-
Nagesh K. Mahanthappa,
Interim CEO and President -
Public Equities, L.P.Artal ...,
-
Junlin Ho,
GENERAL COUNSEL -
Caryn Parlavecchio,
CHRO